Virtual Library

Start Your Search

Michal Urda

Author of

  • +

    P3.13 - Targeted Therapy (Not CME Accredited Session) (ID 979)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
    • +

      P3.13-11 - Advanced Nsclc Treated with Gefitinib or Erlotinib for Five Years or Longer - Retrospective Slovakian Study (ID 14100)

      12:00 - 13:30  |  Author(s): Michal Urda

      • Abstract
      • Slides


      Median PFS in the key phase III trials with gefitinib or erlotinib for advanced NSCLC with EGFR sensitizing mutations was less than 12 months. There are only a few data about the treatment results and toxicity of long-term treatment lasting 5 years or over. Purpose of this study was to find patients treated with either gefitinib or erlotinib for at least 5 years and to evaluate the treatment results in this group of patients.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      Retrospective multicentre study, approved by the Ethical Committee of the Specialised Hospital of St Zoerardus Zobor, Nitra. All thoracic oncology centres in Slovakia were involved. Data regarding patients were obtained from the databases of participating institutions and patient files. Descriptive statistics was used for the data analysis.

      4c3880bb027f159e801041b1021e88e8 Result

      Seven patients were included. Patients characteristics and the treatment results are summarised in the Table. Median PFS in this exceptional group was not reached, but it will be over 75 months. There was only one patient with the decreased dose of erlotinib (from 150 to 100 mg QD) due to skin toxicities. All the other patients had the common and manageable grade I – II toxicities only, and there were no unexpected drug-related AEs.


      8eea62084ca7e541d918e823422bd82e Conclusion

      In our group of patients with advanced NSCLC treated with gefitinib or erlotinib for over 5 years the treatment was safe and effective. The NGS analysis of the available samples will be retrospectively done to assess the specific genetic features of these long-term responders.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.